Carlyle Group’s Spruce Biosciences SPRB Stock Holding History

Carlyle Group’s Portfolio SPRB Stock Details SPRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.09M	Hold	38,620	–	–	0.02%	7
2026 Q1	$2.52M	Hold	38,620	–	–	0.02%	9
2025 Q4	$3.3M	Sell	38,620 -2,857,898	-99%	-$306M	0.02%	9
2025 Q3	$24.8M	Buy	+2,896,518	New	+$25.6M	0.57%	4
2025 Q2	–	Sell	-38,620	Closed	-$840K	–	24
2025 Q1	$840K	Hold	38,620	–	–	0.02%	20
2024 Q4	$1.22M	Hold	38,620	–	–	0.03%	20
2024 Q3	$1.32M	Hold	38,620	–	–	0.14%	18
2024 Q2	$1.52M	Hold	38,620	–	–	0.14%	19
2024 Q1	$2.28M	Hold	38,620	–	–	0.14%	21
2023 Q4	$8.37M	Hold	38,620	–	–	0.4%	14
2023 Q3	$6.46M	Hold	38,620	–	–	0.28%	16
2023 Q2	$6.23M	Hold	38,620	–	–	0.22%	16
2023 Q1	$6.4M	Buy	+38,620	New	+$7.17M	0.19%	19

Other funds holding SPRB

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return

Carlyle Group's SPRB Position: Q2 2026 in Review

Carlyle Group held its Spruce Biosciences (SPRB) position steady in Q2 2026 at 38,620 shares worth $2.09M. The position accounts for 0.02% of the portfolio, ranked #7.

Carlyle Group first reported a position in SPRB in Q1 2023 and has held it in 13 quarters since. The position peaked at $24.8M in Q3 2025. 57 funds tracked by Wall St. Rank hold SPRB as of Q2 2026.

Carlyle Group held 38,620 shares of Spruce Biosciences worth $2.09M as of Q2 2026.
Carlyle Group left its Spruce Biosciences share count unchanged in Q2 2026.
Spruce Biosciences made up 0.02% of Carlyle Group's portfolio in Q2 2026, its #7 holding.
Carlyle Group first reported a position in Spruce Biosciences in Q1 2023 and has held it in 13 quarters since.
Carlyle Group's Spruce Biosciences position peaked at $24.8M in Q3 2025.
57 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2026.

Based on Carlyle Group's 13F filing for Q2 2026, filed 7 Aug 2026.